Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) (NCT06898957)
A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
The primary objective of this study is to evaluate the safety and tolerability of tarlatamab in combination with YL201 with or without anti-PD-L1.
Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (6 items).
Location: City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistCheck every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).
Usually NOT eligible if any of the following apply:
- Exclusion Criteria:
- Prior delta-like ligand 3 (DLL3) or B7 homolog 3 (B7-H3) targeted therapy.
- Prior exposure to topoisomerase I inhibitors or antibody-drug conjugate (ADC) with topoisomerase I inhibitor payload.
- Symptomatic central nervous system (CNS) metastases. Note: Participants with asymptomatic brain metastases are eligible as defined in the protocol.
- History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required corticosteroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Baseline requirement of supplemental oxygen.
🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.
📍 All Participating Trial Locations (36 Sites)
Showing the first 25 of 36 sites.
- City of Hope Orange County Lennar Foundation Cancer Center — Irvine, California
- Yale New Haven Hospital — New Haven, Connecticut
- Moffitt Cancer Center — Tampa, Florida
- Dana Farber Cancer Institute — Boston, Massachusetts
- Siteman Cancer Center — St Louis, Missouri
- Sanford Roger Maris Cancer Center — Fargo, North Dakota
- Cleveland Clinic Foundation — Cleveland, Ohio
- Sanford Oncology Clinic and Pharmacy — Sioux Falls, South Dakota
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Swedish Medical Center — Seattle, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- CHU de Quebec Hopital de l Enfant Jesus — Québec, Quebec
- Shandong Cancer Hospital — Jinan, Shandong
- West China Hospital of Sichuan University — Chengdu, Sichuan
- Fujian Cancer Hospital — Fuzhou,
- Institut Bergonie — Bordeaux,
- Centre Leon Berard — Lyon,
- Institut Universitaire du Cancer Toulouse Oncopole — Toulouse,
- Gustave Roussy — Villejuif,
- Universitaetsklinikum Essen — Essen,
- Henry Dunant Hospital Center — Athens,
- Alexandra Hospital — Athens,
- European Interbalkan Medical Center — Thessaloniki,
- Iatriko Diavalkaniko Thessalonikis — Thessaloniki,
- Semmelweis Egyetem — Budapest,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Small Cell Lung Cancer
- Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy — New Haven, Connecticut
- Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) — Chandler, Arizona
- Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment — Birmingham, Alabama
- Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy — Tucson, Arizona
- Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) — Goodyear, Arizona
Explore by condition: All Small Cell Lung Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.